Literature DB >> 6333948

Prevention of immune precipitation by purified classical pathway complement components.

J K Naama, A O Hamilton, A C Yeung-Laiwah, K Whaley.   

Abstract

The role of the classical pathway of complement in the prevention of immune precipitation has been investigated using purified complement components and immune complexes (IC) consisting of rabbit anti-BSA and BSA. C1 reduced the rate of immune precipitation. As C1q, EDTA treated C1 or C1-inhibitor treated C1 were unable to retard the precipitation of IC, it was concluded that the intact C1 molecule was required for this function. Use of phenylmethylsulphonyl fluoride and benzamidine showed that the enzymatic site on C1 was not required for this activity. C4 and C2 did not affect immune precipitation significantly when C1 was present at the concentrations present in serum. When C3 was added to C1, C4 and C2 precipitation of IC did not occur. These data demonstrate that classical pathway activation alone is sufficient for the prevention of immune precipitation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333948      PMCID: PMC1577075     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s.

Authors:  A Reboul; G J Arlaud; R B Sim; M G Colomb
Journal:  FEBS Lett       Date:  1977-07-01       Impact factor: 4.124

2.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies.

Authors:  K Yonemasu; R M Stroud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

5.  The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1.

Authors:  D Yasmeen; J R Ellerson; K J Dorrington; R H Painter
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

6.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.

Authors:  M Takahashi; S Takahashi; V Brade; V Nussenzweig
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Purification and structural analysis of the fourth component of human complement.

Authors:  C Bolotin; S Morris; B Tack; J Prahl
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

8.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

9.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

10.  Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

Authors:  M Takahashi; B F Tack; V Nussenzweig
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

View more
  14 in total

1.  The relative roles of C4A and C4B in prevention of immune precipitation, solubilisation and immune adherence.

Authors:  E R Holme; J Veitch; A Johnston; I C McKay; K Whaley
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

2.  Modulation of monocyte complement synthesis by interferons.

Authors:  A O Hamilton; L Jones; L Morrison; K Whaley
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

3.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

4.  Immunohistochemical localization of a plasma protein (glycoprotein 60) which inhibits complement-mediated prevention of immune precipitation.

Authors:  G P Sandilands; A E Ahmed; M R Griffiths; K Whaley
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

5.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

6.  BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells.

Authors:  L Varga; E Thiry; G Füst
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

7.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

8.  Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

Authors:  M T Aguado; M Mannik
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

9.  An inhibitor of complement-mediated prevention of immune precipitation in rheumatoid arthritis--relationship to disease activity and systemic manifestations.

Authors:  W S Mitchell; J Veitch; J Hunter; A Zoma; H Capell; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

10.  Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; K Whaley
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.